Retroviral vectors are currently the most important and best characterized tools for ex vivo genetic modification of hematopoietic progenitor/stem cells. As a prerequisite for clinical applications, large volumes of high-titer vector supernatants have to be generated in compliance with 'GMP' guidelines. This goal can be reached using a carefully selected producer cell clone and a conventional large-scale cell culture system. The retroviral vector SF1m provides efficient expression of the human multidrug resistance 1 (MDR1) gene in hematopoietic progenitor/stem cells in vitro and in NOD/SCID mouse repopulating human cells in vivo. Currently, a clinical phase I/II study is in preparation to test whether intensified consolidation chemotherapy is enabled by autologous transplantation of peripheral blood progenitor/stem cells that have been genetically modified with SF1m. Using multi-tray cell factories Ͼ19 l of serum-free vector containing supernatant were generated from cells of a previously established SF1m-producer clone, based on the PG13 packaging cell line. Testing of the final samples revealed sufficient quality (Ͼ1.5 ؋ 10 6 infectious particles/ml) for clinical scale transduction of CD34 ؉ cells. Results from the production runs and the applied biosafety concept are described. Bone Marrow Transplantation (2000) 25, Suppl. 2, S114-S117.
Retroviral gene transfer and expression of the multidrug resistance 1 gene (MDR1) in hematopoietic cells might enable intensified post-transplantation chemotherapy and allow selection of gene-modified cells in vivo. 1 Preclinical studies and pioneering clinical trials indicate that improvements in vector design, in vector stock generation as well as in gene transfer protocols are necessary to design gene therapy trials that result in clinical benefit for the patients enrolled.
We have developed and characterized retroviral vectors that mediate strong transgene expression in early human hematopoietic cells and in their progeny. These novel vectors were named FMEV, because they combine the Correspondence: Dr H-G Eckert, EUFETS GmbH, Vollmersbachstr. 66, 55743 Idar-Oberstein, Germany enhancer/promoter sequences derived from Friend mink cell focus forming viruses (such as the spleen focus-forming virus) with the primer binding site of the murine embryonic stem cell virus. 2, 3 FMEV vectors mediate significantly improved gene expression levels in human hematopoietic cells in vitro compared to conventional constructs based on the Moloney murine leukemia virus. 4 The vector SF1m used in this study expresses the MDR1-cDNA from an FMEV-based construct. After transduction with MDR1, human CD34
+ cells can be selected in vitro and in vivo using cytotoxic agents that are recognized by the MDR1-encoded drug efflux pump, including taxanes, vinca alkaloids, anthracyclines, podophyllotoxins and colchicine. [5] [6] [7] [8] Sustained expression of SF1m could previously be demonstrated in engrafted human cells 5 to 13 weeks after xenotransplantation in nonobese-diabetic/LtSzscid/scid (NOD/SCID) mice. 9 Consequently, this vector will be included in novel clinical studies that are currently under preparation to test the concept of in vivo selection of genetically engineered, multidrug-resistant hematopoietic cells.
The production procedure for clinical grade vector containing supernatant has to meet special requirements. Biological safety and compliance with the guidelines for 'good manufacturing practice' (GMP) have to be guaranteed, but also potential immunological problems in the patient and the compatibility with efficient transduction protocols have to be addressed. Serum-free preparations of vectors produced from a third-generation packaging cell line that provides the envelope protein of gippon ape leukemia virus (GALV) for pseudotyping of vector particles is favored by us and several other groups for the transduction of CD34 + progenitor/stem cells. [10] [11] [12] [13] [14] [15] We report here our results of the production run of the retroviral vector SF1m. After the establishment and banking of a high-titer producer cell clone and an intensive evaluation of the most advantageous cell culture parameters, we have performed two production runs on 40-tray cell factories (NUNC, Wiesbaden, Germany) to generate 19.2 l vector containing supernatant with sufficient quality (Ͼ1.5 × 10 6 functional infectious particles/ml) for the transduction of progenitor/stem cells in a clinically relevant scale.
Using an optimised protocol for the retroviral transduction of Ͼ10 8 human CD34 + cells 16 and retroviral vector stocks generated on multi-tray cell factories according to GMP guidelines, we were able to transduce up to 30% of NOD/SCID mouse repopulating cells.
Materials and methods

Producer cell clone establishment
All cell lines used in this study were purchased from ATCC or EACC. Prior to expansion and cell banking, cells were tested for sterility, mycoplasm contamination as well as replication-competent retrovirus contamination. After expansion, master-and working-cell banks were established and cryopreserved in liquid nitrogen. Culture of the retroviral packaging cell lines and the human fibrosarcoma cell line HT1080 was performed in Dulbecco's modified Eagle's medium (DMEM) with Glutamax (Life Technologies, Eggenstein, Germany), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (PAA, Linz, Austria), tested for species-specific virus contamination in advance. Cells were maintained at 37°C and 5% CO 2 .
The pSF1mdr1 plasmid was transfected into the ecotropic GP+env86 packaging cell line, using the SuperFect transfection reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Subsequently, transient supernatant was harvested, filtered (0.45 m) (Gelmann Sciences, Ann Arbor, MI, USA) and used to transduce amphotropic GP+envAM12 (GA12) producer cells. Stable retroviral vector supernatant from the GA12 was then used to infect the GALV-based producer cell line PG13. Hightiter retroviral PG13 producer clones were established by fluorescence-activated single cell sorting of Rhodamine-123 dull cells on a FACSVantage (Becton Dickinson, Heidelberg, Germany).
Retroviral producer clones were expanded and supernatant from Ͼ80 clones was harvested, filtered (0.45 m) and stored at −80°C until titered. Titers were determined by infection of the human fibrosarcoma cell line HT1080 and subsequent detection of Rhodamine-123 efflux activity on a FACSCalibur (Becton Dickinson). Consequently, from all tested clones, one best clone PG13/SF1m (CS78) was chosen for the generation of clinical grade retroviral vector stocks.
Generation of retroviral vector stocks on multi-tray cell factories
Retroviral producer cells PG13/SF1M (CS78) were plated at a cell density of 1.5 × 10 4 cells/cm 2 (first production run) or 1.2 × 10 4 cells/cm 2 (second production run) on 40-tray cell factories (NUNC). Seeding, washing and harvest of cells as well as collection of retroviral supernatant was performed according to the manufacturer's guidelines using the NUNC starter kit and a peristaltic pump. Cells were expanded in FBS-containing DMEM for approximately 80 h at 37°C and 5% CO 2 resulting in a confluent layer.
Serum-free retroviral supernatant was generated on confluent layers after three washing steps with PBS (Life Technologies) and a complete medium change to 0.1 ml/cm 2 of X-VIVO 10 medium (BioWhittaker, Walkersville, MD, USA), containing 2 mm l-glutamine (Life Technologies). Vector supernatant was harvested after a 16 h exposure at 32°C. During day time, cells were kept in DMEM (+ 10% FBS). From each cell factory, four retroviral vector stocks were harvested over 4 consecutive nights.
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Following harvest, each retroviral supernatant was immediately filtered (0.45 m) (Gelmann Sciences) and stored in 1 l cryo-bags (Stedim, Concord, USA) at −80°C until titered and pooled. After conclusion of the last harvest, all cryopreserved vector stock batches were thawed in a water bath and pooled to one final end-product using an entirely closed bag system. Aliquots of 100 ml of the final endproduct were filled in cryo-bags (Stedim) and stored at −80°C. Titers of the single harvests as well as of the pooled end-product were determined by infection of the human cell line HT1080 and subsequent detection of Rhodamine-123 efflux activity on a FACSCalibur (Becton Dickinson).
Results
Producer cell line establishment
Subsequently, 86 producer cell clones were expanded and tested for efficient vector packaging. Approximately 30% of the clones tested revealed retroviral titers higher than 10 5 infectious particles/ml, but only two of these producer cell clones showed satisfactory vector packaging (Ͼ4 × 10 5 infectious particles/ml) for clinical scale production (see Figure 1) . As demonstrated by Southern blot analysis, one of these best two clones (termed PG13/SF1m (CS78)) contained only a single intact vector copy integration (data not shown). Therefore, this clone was selected for clinical scale vector production.
Clinical scale vector production
PG13/SF1m (CS78) cells were expanded to establish a primary seed bank (PSB). Subsequently, a single vial of the PSB was used to establish a master cell bank (MCB) in compliance with GMP directives. This MCB will serve as a reservoir for the initiation of numerous vector production runs.
To harvest a maximum of infectious vector particles in a minimum of serum-free cell culture supernatant, culture conditions for the PG13/SF1m producer clone were carefully optimised (data not shown). Consequently, a combination of the most advantageous parameters was used for large-scale retroviral vector production as described in Materials and methods.
Two vector production runs were performed on 40-tray cell factories according to GMP guidelines. Each single harvest comprised 2.4 l of vector containing supernatant. Retroviral vector stocks were filtered and frozen as one single batch on each of 4 consecutive days. Retroviral titers ranged from 1.4 to 2.8 × 10
6 infectious viral particles/ml ( Figure 2a) . As a result of method standardization, the two production runs showed similar kinetics, reaching the maximum of retroviral vector release at day 2. Even the number of retroviral particles in the harvested supernatant did not differ significantly between the two runs. To gener- ate a homogeneous end-product, vector batches of the 4 days were thawed, pooled and filtered. Altogether, 180 cryo-bags were filled with 100 ml vector containing supernatant and stored at −80°C.
Throughout the end-filling procedure, test samples were collected from each fifth bag and analyzed for vector titer. Titers ranged from 1.4 to 1.8 × 10 6 infectious viral particles/ml (Figure 2b ) which is sufficient for efficient clinical scale progenitor/stem cell transduction. No significant difference could be observed between the titer of the test samples and the titer of the final aliquots (bag Nos 1, 90 and 180) (Figure 2b ). End-filling-related loss of infectious particles comprised approximately 20%, resulting in a final amount of 3 × 10 10 infectious vector particles being stored after the described production procedure.
Biosafety aspects
The biological safety of ingredients used for the manufacture of clinically applicable products, such as retroviral vector supernatant as well as gene-modified cell material has to be confirmed. We suggest testing of each packaging cell line used for the establishment of a PSB with regard to sterility, presence of mycoplasm and for formation of replication-competent retrovirus (RCR). In our biosafety concept, the following aspects were additionally included: all cell culture ingredients had to be sterile and free of adventitious viruses. Serum and trypsine were analyzed in advance for the presence of species-specific viruses. The PSB and the MCB were checked for sterility, mycoplasm contamination as well as RCR formation. The MCB was additionally checked for cell identity, tested for adventitious viruses and in further specific analyses for bovine, porcine and murine virus contamination. End of production cells (EPC), harvested after conclusion of the vector production runs were analyzed separately for the occurrence of RCR. Finally, the retroviral supernatant end-product was tested for sterility, for the presence of endotoxin, mycoplasm and for RCR formation.
The combination of all these quality and biosafety tests should guarantee the absence of known biological contaminants in the final end-product.
Discussion
Gene therapy trials initiated to evaluate the applicability of retrovirus-mediated MDR1 gene transfer into hematopoietic stem/progenitor cells has to date failed to demonstrate a significant clinical benefit. [17] [18] [19] [20] Although the optimised retroviral vector SF1m has been described and extensively proven in preclinical model systems, 2,4,9 several additional prerequisites have to be fulfilled to ensure successful clinical gene therapy studies.
Crucial prerequisites for the efficient gene modification of human hematopoietic progenitor/stem cells are the establishment of a highly efficient transduction protocol as well as the generation of high-titer retroviral vector supernatant especially with regard to clinical acceptable conditions. 21 Also, it is necessary to produce large quantities of retroviral vector stocks without loss of quality. The results presented here clearly demonstrate that cautious selection of retroviral producer clones in combination with a well established large-scale cell culture system allow for a very efficient production of large volumes of SF1m retroviral vector stocks. To meet the requirements of state of the art clinical scale CD34
+ transduction protocols, we focused on the generation of serum-free GALV-pseudotyped retroviral vector stocks according to GMP guidelines. Due to the extensive biosafety testing that is performed on all ingredients and end-products, we can ensure the absence of contaminating adventitious agents. Using intensively optimized culture conditions, we were able to put 3 × 10 10 infectious vector particles in storage, generated in two production runs. Titer of the cryopreserved homogeneous end-product was approximately 1.7 × 10 6 vector particles/ml. According to our own experience with a CD34
+ transduction protocol that works efficiently at high cell concentrations, this clearly exceeds the number of vector particles necessary for the clinical phase I/II study planned.
Using FMEV vectors and our carefully optimised retroviral vector stock generation in compliance with GMP guidelines, we were able to reach gene transfer efficiencies up to 50% into human CD34
+ cells in vitro. Furthermore, data from NOD/SCID mouse repopulation assays provide strong evidence that using our vector containing supernatant and an optimal transduction protocol, the multilineage engraftment potential of the gene modified CD34
+ cells was maintained; and up to 30% of the SCID repopulating cells were positive for MDR1-specific sequences. These results stand in clear correlation to previously published data from Schiedlmeier et al 9 and van Hennik et al, 11 where high efficient gene transfer into NOD/SCID repopulating cells was reported, using FMEV-based retroviral vector constructs.
We expect that our results will help to demonstrate that myeloprotection mediated by MDR1 gene transfer is a feasible goal when adequate conditions are combined to meet the requirements for efficient retroviral transduction of hematopoietic progenitor/stem cells.
